Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR001 for the patients with a severe form of scleroderma. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Wellesley, Massachusetts.
Talaris Therapeutics, Inc. Frequently Asked Questions
What is the ticker symbol for Talaris Therapeutics, Inc.? What does TALS stand for in stocks?
TALS is the stock ticker symbol of Talaris Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.
What is the market capital of Talaris Therapeutics, Inc. (TALS)?
As of Wed Jul 31 2024, market cap of Talaris Therapeutics, Inc. is 73.33 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.
What is the fair value of TALS stock?
You can check TALS's fair value in chart for subscribers.
Is Talaris Therapeutics, Inc. a good stock to buy?
The fair value guage provides a quick view whether TALS is over valued or under valued. Whether Talaris Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Talaris Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TALS.